Serina Therapeutics, Inc. (SER) stock

SERNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30

$1.39−0.02 (-1.42%)

Close on Nov 13, 2026Market cap $35.31MP/E –Yield –

Serina Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Serina Therapeutics's price to sales ratio was 150.7× on Apr 30, 2026, against 6.8× a year earlier. Over the last 5 years it ranged from 0.3× to 477.9×, with a median of 111.4×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Apr 30, 2026	150.7×	+137.5
2025	Jan 31, 2025	13.2×	−0.9
2024	Dec 31, 2024	14.1×	−183.3
2023	Dec 29, 2023	197.4×	−197.8
2022	Dec 30, 2022	395.2×	+244.8
2021	Dec 31, 2021	150.4×	+74.2
2020	Dec 31, 2020	76.2×	+30.3
2019	Dec 31, 2019	45.9×	−25.9
2018	Dec 31, 2018	71.9×	–

Where these numbers come from

Parsed from the XBRL in Serina Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing